The flow cytometric immune phenotyping revealed significantly higher levels of Tregs in adenocarcinoma patients (Fig. 1a, c) but no difference in the expression of the lymphocytic surface markers CD3 or CD4 (Additional file 1: Table S1). The gene discussed is CD4; the disease is adenocarcinoma.